Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
Intelence | Etravirine | HIV | List with clinical criteria and/or conditions | Complete | ||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete |